Volume 10, Issue 4 (Shenakht Journal of Psychology and Psychiatry 2023)                   Shenakht Journal of Psychology and Psychiatry 2023, 10(4): 119-132 | Back to browse issues page


XML Persian Abstract Print


Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:

Hoghoughi N, Shams Alizadeh N, Maroufi A, Rezaei F, Esfandiari G. Effectiveness of spironolactone on schizophrenia symptoms: A double-blind randomized clinical trial. Shenakht Journal of Psychology and Psychiatry 2023; 10 (4) :119-132
URL: http://shenakht.muk.ac.ir/article-1-1373-en.html
1- Resident, Department of Psychiatry, Kurdistan University of Medical Sciences, Sanandaj, Iran
2- Associate Professor, Department of Psychiatry, Kurdistan University of Medical Sciences, Sanandaj, Iran , Nshamsalizadeh@yahoo.com
3- Associate Professor, Department of Psychiatry, Kurdistan University of Medical Sciences, Sanandaj, Iran
4- Professor, Department of Psychiatry, Tehran University of Medical Sciences, Tehran, Iran
5- MSc, Spiritual Health Research Center, Kurdistan University of Medical Sciences, Sanandaj, Iran
Abstract:   (598 Views)
Introduction: Schizophrenia is a mental disorder in which the facts surrounding a person are interpreted as abnormal. The treatment aims to reduce symptoms and the possibility of disease recurrence.
Aim: This study aimed to investigate the effectiveness of spironolactone on schizophrenia symptoms.
Method: In this double-blind analytical and clinical study, 44 patients were randomly divided into two groups. The study was carried out in Quds Hospital and centers for psychiatric patients in Sanandaj city in 2019 and 2020. The number of patients decreased to 32 due to drug side effects and unwillingness to continue treatment. The instrument used was the scale test of positive and negative symptoms of schizophrenia. Datum were analyzed using chi-square and ANOVA with repeated measurements and independent t-tests by SPSS-23 software.
Results: The results showed that out of 44 patients studied, 37 (84.1%) were men and 7 (15.9%) were women. The imbalance was due to the small sample size. There was no significant difference between the two groups in terms of sex distribution, literacy level, marital status, employment history, and background medication use (P>0.05). In addition, there was no significant difference between the two groups in terms of reducing negative symptoms (P=0.666), positive symptoms (P=0.748) and general symptoms (P=0.342).
Conclusion: According to the finding, spironolactone has no significant effect on reducing negative, positive, and general symptoms. Therefore, it is suggested to carry out more studies using this drug (by removing the limitations of this study) and other drugs.

Full-Text [PDF 694 kb]   (207 Downloads)    
Type of Study: Applicable | Subject: Special
Received: 2023/03/10 | Accepted: 2023/07/26 | Published: 2023/09/17

Add your comments about this article : Your username or Email:
CAPTCHA

Send email to the article author


Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

© 2024 All Rights Reserved | Shenakht Journal of Psychology and Psychiatry

Designed & Developed by : Yektaweb